US Government Role in HIV/AIDS drugs - from ACTIS and CRISP

[James Love <love@cptech.org>]

  US government sponsorship of clinical trials and number of US
     federal grants in CRISP database, for 14 HIV/AIDS Drugs
           Information from ACTIS and CRISP databases

                                
          James Love and  Thirukumaran Balasubramaniam
                        November 19, 1999

           Preliminary, version 1.0


The following are some data on the US government's role in the
development in 14 HIV/AIDS drugs.  

     The ACTIS database 

Thirukumaran Balasubramaniam checked the ACTIS database to
determine the number of US federal government sponsored clinical
trials involving a particular drug, and the number of trials
sponsored by non-government entities.  

     Note on the data: The non-government category includes
     Universities.  There may be government funding of the
     non-government sponsored trials, or some mixed funding
     of the government trials.  A few of the government
     sponsored trials were co-sponsored with Universities or
     firms.  If a trial involved more than one drug, as they
     often are, it was included in the report for each drug.

For every one of the 14 drugs a significant number of the
HIV/AIDS clinical trials in the ACTIS database were sponsored by
the US government.  The lowest percent of clinical trials
sponsored by the US government was 40 percent, for Abacavir.  The
highest percent was 69 percent, for ddI.  


     The CRISP database

Thiru also looked at the NIH Computer Retrieval of Information on
Scientific Projects (CRISP) database, running a key word search
on the generic name of the drug in the Historical Award database
(1986-1998), and reports the number of NIH grants in the CRISP
database that have that word(s) in the abstract. 
(https://www-commons.cit.nih.gov/crisp/)


The key data are presented below:

                         Number of
                         trials in
                         ACTIS
                         database            
                         sponsored by        
                         government          Number of
                         and non-            grants in
                         government          CRISP
                         gov/non-gov         database
                          
Nucleoside Analogue                
Reverse Transcriptase    
Inhibitors (RT)          


Zidovudine (AZT)         314/189             1462
Retrovir                 62%

Didanosine (ddI)         131/59              66
Videx                    69%

Zalcitabine ddC)         43/26               6
Hivid                    62%            

Stavudine (d4T)          53/56               158
Zerit                    49%

Lamivudine (3TC)         65/54               191
Epivir                   55%

Abacavir                 19/29               2
Ziage                    40%


Protease Inhibitors 
                    

Saquinavir               25/32               29
Invirase;                44%

Ritonavir                30/28               43
Norvir                   52%


Indinavir                53/54               91
Crixivan                 50%


Nelfinavir               40/41               25
Viracept                 49%
                                                               
Amprenavir               14/11               1
Agenerase                56%


Non-Nucleoside Reverse 
Transcriptase Inhibitors 
(NNRTI) 
  
Nevirapine               42/23               151
Viramune                 65%


Delavirdine              20/20               53
Rescriptor               50%
                                                                  

Efavirenz                20/17               1
Sustiva                  54%
  

See also:

http://www.cptech.org/ip/health/aids/druginformation.html


-------------------------------
James Love 
Center for Study of Responsive Law | Consumer Project on Technology 
P.O. Box 19367, Washington, DC 20036 | http://www.cptech.org
Voice 202/387-8030 | Fax 202/234-5176 | love@cptech.org